Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Substudy by Pride, Yuri B. et al.
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resenting With Isolated Anterior
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TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes
y Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In
yocardial Infarction 38) Substudy
uri B. Pride, MD,* Patricia Tung, MD, MPP,* Satishkumar Mohanavelu, MS,†
afer Zorkun, MD,* Stephen D. Wiviott, MD,† Elliott M. Antman, MD,†
obert Giugliano, MD,† Eugene Braunwald, MD,† C. Michael Gibson, MS, MD,‡
or the TIMI Study Group
oston, Massachusetts
bjectives This study sought to determine angiographic and clinical outcomes among patients
ith acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on
2-lead electrocardiogram (ECG).
ackground In patients with ACS, anterior ST-segment depression on 12-lead ECG may represent
laque rupture with: 1) acute thrombotic occlusion with elevation of cardiac biomarkers (Tn); 2) a
atent artery with Tn; or 3) a patent artery with –Tn.
ethods The TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction 38) enrolled 13,608 ACS pa-
ients. Those with isolated anterior (leads V1 to V4) ST-segment depression were analyzed. Angio-
rams and ECGs were interpreted by local investigators.
esults There were 1,198 (8.8%) patients with isolated anterior ST-segment depression. Of those,
14 (26.2%) had an occluded culprit artery (TIMI ﬂow grade 0/1) and Tn, 641 (53.5%) had a patent
ulprit artery (TIMI ﬂow grade 2/3) and Tn, and 243 (20.3%) had TIMI ﬂow grade 2/3 and –Tn.
mong patients with an occluded artery, the culprit artery was most often the left circumﬂex artery
48.4%). The 30-day incidence of the composite of death and MI was signiﬁcantly higher among pa-
ients with an occluded artery (8.6%) than among those with a patent culprit artery and either Tn
6.3%) or –Tn (2.9%) (3-way p  0.006). Among patients with an occluded artery, the median time
rom ECG to percutaneous coronary intervention was 29.4 h (interquartile range 26.1 to 44.1 h).
onclusions Among ACS patients presenting with isolated anterior ST-segment depression, over
ne-quarter had an occluded culprit artery and elevated cardiac biomarkers. These patients had sig-
iﬁcantly worse clinical outcomes, and few underwent urgent angiography. (J Am Coll Cardiol Intv
010;3:806–11) © 2010 by the American College of Cardiology Foundation
rom the *Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center; †TIMI Study Group,
ardiovascular Divisions, Departments of Medicine, Brigham and Women’s Hospital; and the ‡Beth Israel Deaconess Medical
enter, Harvard Medical School, Boston, Massachusetts. The TRITON–TIMI 38 study was supported by a grant from
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807rompt diagnosis and early reperfusion therapy among
atients with ST-segment elevation myocardial infarction
STEMI) is associated with a reduction in morbidity and
ortality (1–3) and relies on the principle that early reper-
usion of an occluded coronary artery improves clinical
utcomes. However, an estimated 2% to 12% of STEMI are
nitially missed at the time of presentation to the emergency
epartment (4,5). Discharge from the emergency depart-
ent, when compared with hospital admission, for patients
ith STEMI has been associated with a doubling of
ortality (6). Current clinical practice relies heavily on
nitial electrocardiographic changes for the diagnosis of
TEMI, and a significant portion of missed cases might be
ttributable to the limited sensitivity of the traditional
2-lead surface electrocardiogram (ECG), which samples a
elatively small area of the upper anterior thorax for iden-
ifying coronary occlusion (7).
The limited sensitivity and specificity of the 12-lead
CG in diagnosing STEMI is exemplified by the clinical
cenario of isolated anterior ST-segment depression. This
lectrocardiographic finding can represent pathophysiology
cross the spectrum of acute coronary syndrome (ACS):
) plaque rupture with a patent artery and no elevation of
ardiac biomarkers leading to unstable angina; 2) a patent
rtery supplying the anterior myocardium with elevated
ardiac biomarkers (i.e., non-STEMI); or 3) acute throm-
otic occlusion of the posterior circulation with elevated
ardiac biomarkers (i.e., posterior STEMI). Previous studies
ave demonstrated that acute thrombotic occlusion of a
essel supplying the posterior wall is particularly challenging
o diagnose, both because of its inconsistent presentation on
he ECG and the relatively small contribution of the
osterior wall to the QRS complex in the traditional
nterior pre-cordial leads (8).
The goal of this analysis was to determine the angio-
raphic and clinical outcomes among patients with ACS
resenting with isolated anterior ST-segment depression on
2-lead ECG.
ethods
he TRITON–TIMI 38 (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
nrolled patients with moderate- to high-risk ACS sched-
led to undergo percutaneous coronary intervention (PCI)
9). The patient population has been previously described
10). Briefly, the inclusion criteria for patients with unstable
onsulting fees from Sanofi-Aventis, AstraZeneca, and ARENA, and has received
ecture fees from Eli Lilly and Company, Daiichi-Sankyo, AstraZeneca, and Novartis.
r. Giugliano has received lecture fees from Sanofi-Aventis, Merck, and Bristol-
yers Squibb, is a consultant for Merck, HeartScape, Sanofi-Aventis, Daiichi-
ankyo, and Angel Med, and has participated in clinical trials/research support for
angina or non-STEMI were ischemic symptoms lasting 10
in or more and occurring within 72 h before randomiza-
ion, a TIMI risk score of 3 or more (11), and either
T-segment deviation of 1 mm or more or elevated levels of
cardiac biomarker of necrosis. Patients with STEMI could
e enrolled within 12 h after the onset of symptoms if
rimary PCI was planned or within 14 days after receiving
edical treatment for STEMI.
For the present analysis, only patients with isolated
nterior ST-segment depression in leads V1 to V4 were
ncluded. Patients with ST-segment elevation in other leads
ere excluded. Electrocardiograms and angiograms were
nterpreted locally by the enrolling physician. Flow in the
ulprit artery undergoing PCI was graded according to the
IMI flow grade (TFG) criteria (1). Patients were grouped
nto 3 categories based on initial TFG in the culprit artery
nd initial serum cardiac biomarkers: 1) TFG 0/1 and
levated cardiac biomarkers (Tn); 2) TFG 2/3 and Tn;
nd 3) TFG 2/3 and no eleva-
ion of cardiac biomarkers
–Tn). As an estimate of infarct
ize, the ratio of the peak serum
oncentration of creatine kinase-
yocardial band fraction to the
pper limit of normal was calcu-
ated among the groups.
As an internal control, the
ubset of patients with isolated
nferior ST-segment depression
as also evaluated for the pres-
nce or absence of elevated car-
iac biomarkers and an occluded
r patent culprit artery at the
ime of angiography.
All continuous variable values
re reported as the mean  SD.
he chi-square test was used for the analysis of categorical
ariables. The Kruskal-Wallis test was performed for the
nalysis of continuous variables. Bonferroni adjustments were
ade when appropriate. Hazard ratios were calculated using
he Cox proportional hazards model. Multivariable logistic
egression was used to adjust for differences in baseline char-
cteristics. A p value of 0.05 was considered significant.
esults
aseline characteristics. There were 13,608 patients en-
olled in the study, of whom 1,198 (8.8%) had isolated
aiichi-Sankyo and Merck. All other authors report that they have no relationships
o disclose.
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Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ECG  electrocardiogram
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TFG  Thrombolysis In
Myocardial Infarction flow
grade
TIMI  Thrombolysis In
Myocardial Infarction
Tn  cardiac biomarkersccepted May 15, 2010.
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808nterior ST-segment depression at presentation. Patients
resenting with isolated anterior ST-segment depression
nd a patent culprit artery at the time of angiography had a
igher incidence of hypertension and hypercholesterolemia
han patients with an occluded artery did at the time of
ngiography (Table 1). Otherwise, the baseline characteris-
ics were similar between the groups.
ngiographic outcomes. Of the 1,198 patients with isolated
nterior ST-segment depression, 314 (26.2%) had an oc-
luded culprit artery (TFG 0/1) at the time of angiography
nd Tn at presentation, 641 (53.5%) had a patent culprit
rtery (TFG 2/3) at the time of angiography and Tn at
resentation, and 243 (20.3%) had a patent culprit artery at
he time of angiography and –Tn at presentation (Fig. 1).
one of the patients with an occluded artery had negative
ardiac biomarkers. Among the 314 patients with an oc-
luded culprit artery, the occluded artery was most often the
eft circumflex artery (n  152, 48.4%), followed by the left
nterior descending artery (n  106, 33.8%) and the right
oronary artery (n  56, 17.8%) (Fig. 2).
Among the 270 patients who presented with isolated
nferior ST-segment depression, 9 (3.3%) had an occluded
ulprit artery and Tn, 226 (83.7%) had a patent culprit
rtery and Tn, and 35 (13.0%) had a patent culprit artery
nd –Tn.
linical outcomes. The 30-day incidence of the composite
f death and MI was significantly higher among patients
ith an occluded artery than among those with a patent
ulprit artery with either Tn or –Tn (8.6%, 6.3%, and
.9%, respectively; 3-way p  0.006) (Fig. 3). Patients with
n occluded artery and Tn were significantly more likely
o have death or MI than those with a patent artery and –Tn
Table 1. Baseline Characteristics
TFG 0/1, Tn
(n  314)
Age, yrs 62 (11.28)
Male sex 71%
White 97%
BMI, kg/m2 28 (4.6)
Medical history
Diabetes mellitus 18%
Hypertension 60%
Hypercholesterolemia 50%
Prior MI 15%
Current smoker 33%
Prior CABG 3%
Multivessel disease 15%
Creatinine clearance, ml/min 101 (37.8)
Glycoprotein IIb/IIIa inhibitor use 56%
Values presented as mean (SD) or % unless otherwise noted.
BMI body mass index; CABG coronary artery bypass graft surge
flow grade; Tn cardiac biomarkers.hazard ratio [HR]: 3.06, 95% confidence interval [CI]:.33 to 7.03, p  0.008) even after adjusting for differences
n baseline characteristics (HRadjusted: 3.21, 95% CI: 1.37 to
.49, p  0.007). Patients with an occluded culprit artery
nd elevated cardiac biomarkers were more likely to have
eath and MI than those with a patent artery and elevated
iomarkers (HR: 1.39, 95% CI: 0.85 to 2.26, p  0.187),
lthough the difference was not statistically significant.
owever, after adjusting for differences in baseline charac-
TFG 2/3, Tn
(n  641)
TFG 2/3, –Tn
(n  243) p Value
63 (10.7) 63 (10.7) 0.517
66% 61% 0.066
95% 97% 0.270
28 (5.0) 28 (4.2) 0.581
23% 20% 0.210
70% 72% 0.002
54% 60% 0.047
15% 21% 0.092
31% 30% 0.668
5% 7% 0.070
13% 14% 0.361
100 (39.0) 97 (31.5) 0.440
52% 25% 0.001
myocardial infarction; TFG Thrombolysis In Myocardial Infarction
Figure 1. Flow of Patients
Of patients enrolled in the TRITON–TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction 38), 8.8% had isolated anterior ST-
segment depression. NSTEMI  non–ST-segment elevation myocardial
infarction; STEMI  ST-segment elevation myocardial infarction; TFG 
Thrombolysis In Myocardial Infarction ﬂow grade; Tn  cardiac biomarkers;ry; MIUA  unstable angina.
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809eristics (HRadjusted: 1.61, 95% CI: 0.97 to 2.66, p 0.062),
he difference tended toward significance. Patients with a
atent culprit artery and Tn were also more likely to have
eath or MI than those with a patent artery and –Tn (HR:
.20, 95% CI: 0.99 to 4.91, p  0.054), and this difference
as mildly attenuated after adjusting for differences in
aseline characteristics (HRadjusted: 2.06, 95% CI: 0.91 to
.64, p  0.082).
There was no statistically significant difference in the
ncidence of periprocedural MI (3-way p  0.39), but
atients with an occluded culprit artery had a significantly
igher 30-day incidence of spontaneous MI (3.5%) than
atients with a patent culprit artery andTn (1.1%) or –Tn
0.0%, 3-way p  0.002) (Fig. 4). This was driven predom-
nately by an increased incidence of definite or probable
tent thrombosis, as defined by the Academic Research
Figure 2. Culprit Artery Locations Among Patients With an
Occluded Artery
Among patients with an occluded artery, the most commonly occluded
artery was the left circumﬂex artery (LCx), followed by the left anterior
descending artery (LAD) and the right coronary artery (RCA).
Figure 3. Short-Term Clinical Outcomes
Patients presenting with an occluded artery and elevated cardiac biomark-
ers had signiﬁcantly worse clinical outcomes than did patients presenting
with a patent artery and either positive or negative cardiac biomarkers.
MI  myocardial infarction; other abbreviations as in Figure 1.onsortium (3.3% vs. 0.1% vs. 0.0%, 3-way p  0.003) at
0 days.
Peak serum creatine kinase-myocardial band concentra-
ions were 3.3 times the upper limit of normal among
atients with an occluded culprit artery and 1.5 times the
pper limit of normal among patients with a patent artery
rrespective of biomarker positivity (p  0.001). When
tratified by culprit artery, the difference in enzymatic
stimate of infarct size was significantly higher among
atients with an occluded artery regardless of the artery
nvolved (Table 2).
ime to treatment. The median time from baseline ECG to
CI for patients with an occluded artery was 29.4 h
interquartile range 26.1 to 44.1 h). None of the patients
ith an occluded artery had an ECG to PCI time 6 h.
iscussion
mong ACS patients with anterior ST-segment depression
n this study, over one-quarter had an occluded culprit artery
nd elevated biomarkers. These patients had significantly
orse short-term clinical outcomes and significantly larger
nfarct size than those with a patent culprit artery. More-
3.5%
4.5%
1.6%
1.1%
4.4%
1.3%
0.0%
2.5%
0.4%
0%
1%
2%
3%
4%
5%
6%
Spontaneous MI Periprocedural MI Death
TFG 0/1 Tn+
TFG 2/3 Tn+
TFG 2/3 Tn-
Figure 4. Short-Term Clinical Outcomes
Patients presenting with an occluded artery and elevated cardiac biomark-
ers had a signiﬁcantly higher incidence of spontaneous myocardial infarc-
tion but no signiﬁcant difference in the incidence of periprocedural
myocardial infarction or mortality. Abbreviations as in Figures 1 and 3.
Table 2. Peak Biomarker Values by Culprit Artery
Peak CK-MB ( ULN) LAD RCA LCx p Value
Occluded culprit artery (TFG 0/1, Tn) 2.5 (4.2) 3.0 (3.2) 4.1 (4.3) 0.001
Patent culprit artery (TFG 2/3, –Tn or Tn) 1.2 (1.6) 1.3 (1.2) 2.3 (3.1)
Values are mean (SD).
CK-MB creatine kinase-myocardial band fraction; LAD left anterior descending artery;
LCx left circumflex artery; RCA right coronary artery; –Tn negative cardiac biomarkers;
Tn  elevated cardiac biomarkers; ULN  upper limit of normal; other abbreviations as inTable 1.
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810ver, very few patients with anterior ST-segment depression
nd an occluded culprit artery were recognized by clinicians
s necessitating urgent angiography as demonstrated by the
ignificant median delay from ECG to PCI.
The median time from the diagnostic ECG to PCI in the
resent study was over 29 h, and it is possible that a
ignificant benefit in clinical outcome would be observed if
he presence of an occluded artery had been diagnosed at the
ime of presentation and emergent revascularization ensued.
urrent American College of Cardiology/American Heart
ssociation guidelines recommend a door-to-balloon time
f 90 min or less for STEMI patients undergoing primary
CI (12). Multiple studies have demonstrated that treatment
elays result in greater morbidity and mortality (13–15). In
hose treated with primary PCI, each 30-min delay from
ymptom onset to treatment has been estimated to increase
he relative risk of 1-year mortality by 7.5% (16). Thus, even
mall changes in door-to-balloon time may have a large
mpact on survival.
The results presented here corroborate findings from
n analysis of non-STEMI patients enrolled in the
ARAGON-B (Platelet IIb/IIIa Antagonism for the Re-
uction of Acute Coronary Syndrome Events in a Global
rganization Network) trial, in which 27% of patients had
n occluded culprit artery at the time of angiography (17).
uch patients had significantly larger infarct size and higher
isk-adjusted 6-month mortality than those with a patent
ulprit artery. That such patients were more likely to have
ulprit lesions in the posterior circulation is not surprising,
s the difficulty in diagnosing MI involving the posterior
irculation is well documented. In the Diltiazem Reinfarc-
ion study, 46% of patients initially classified as having
nterior non–Q-wave MIs were later found to have poste-
ior STEMI as evidenced by evolution of ECG changes and
ardiac biomarkers (8). In patients with left circumflex
rtery occlusion, the infarct may affect an electrocardio-
raphically silent area of the heart, and the traditional
2-lead ECG may be entirely normal. Although nearly half
f patients with an occluded artery in the current analysis
ad occlusion of the left circumflex coronary artery, fully
ne-third of patients had left anterior descending coronary
rtery occlusion. Evidence from a PCI registry suggests that
% of patients with proximal left anterior descending
oronary artery occlusion may present with anterior ST-
egment depression (18). Patients with posterior STEMI
ave been demonstrated to have increased mortality com-
ared with those without evidence of posterior infarction,
ikely resulting at least in part from a delay in recognition as
ell as complications such as left ventricular dysfunction,
itral regurgitation, ventricular septal defect, or bradycar-
ia, depending on the affected artery (19,20).
To examine whether arterial occlusion was an epiphe-
omenon associated with ST-segment depression alone or
as specific to the anterior pre-cordial leads, we examined The angiographic outcomes among patients presenting with
solated inferior ST-segment depression. That less than 5%
f patients presenting with inferior ST-segment depression
ad an occluded culprit artery, as compared with the more
han one-quarter with anterior ST-segment depression,
uggests that it is electrocardiographic location, rather than
T-segment depression in and of itself, that connotes the
ossibility of arterial occlusion.
There were no substantial baseline clinical differences
etween patients with an occluded culprit artery and those
ith a patent culprit artery at the time of angiography.
herefore, further diagnostic modalities may be warranted
n the subset of patients with isolated anterior ST-segment
epression. Bedside troponin assays, application of right-
ided or posterior ECG leads, or more liberal use of bedside
chocardiography may be warranted (8,19,21,22).
tudy limitations. This analysis is a nonrandomized retro-
pective analysis, and, as such, it is possible that both
dentified and unidentified confounders may have influ-
nced the outcomes. Strict enrollment criteria are used in
linical trials, and the results observed here might not be
pplicable to all patients in clinical practice. In order to be
ncluded in the analysis, patients had to survive long enough
o undergo angiography, and the distribution of patent and
ccluded arteries among patients who died prior to angiog-
aphy is not known. Thus, there is a component of survival
ias operative here such that the patients in the present
nalysis with a closed artery and elevated biomarkers were
ealthy enough to survive until the time of angiography, a
edian of 29 h later. Because only those patients who
urvived until angiography are included in the analysis, it is
ossible that patients in clinical practice with an occluded
rtery and elevated biomarkers may face a higher risk of
dverse outcomes than observed here. We did not perform
CGs and angiography simultaneously; therefore, a patent
rtery at the time of ECG may have occluded in the time
rom ECG to angiography or vice versa. The presence of
ollaterals was not collected in this study, and collateral
irculation to the left circumflex territory may have led to an
nderappreciation of inferior ST-segment elevation among
atients with left circumflex occlusion.
onclusions
mong ACS patients presenting with isolated anterior
T-segment depression, more than one-quarter had an
ccluded artery at the time of angiography. These patients
ad a significantly higher incidence of death and MI and a
reater peak creatine kinase-myocardial band fraction than
hose with a patent artery. Less than 5% of patients with
n occluded artery were recognized by clinicians as having
n occluded artery and none underwent urgent angiography.
his suggests the need for improved methods to identify
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811atients with isolated anterior ST-segment depression who
ave an occluded artery.
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